Shares of Stifel Financial were moving higher after it reported fourth-quarter adjusted earnings that beat Wall Street ...

Stifel lowered the firm’s price target on Intel (INTC) to $21 from $25 and keeps a Hold rating on the shares. Q4 results were above management ...

Stifel Nicolaus analyst Matthew Smith, CFA maintained a Buy rating on Altria Group (MO – Research Report) today and set a price target of ...

Stifel analyst David Grossman raised the firm’s price target on IBM (IBM) to $271 from $246 and keeps a Buy rating on the ...

Stifel lowered the firm’s price target on Danaher (DHR) to $260 from $265 and keeps a Hold rating on the shares. Danaher ...

Stifel analysts revised the price target for Kirby Corporation (NYSE:KEX) stock, reducing it slightly to $135 from the ...

Stifel chief executive Ron Kruszewski said surging markets have forced firms to be particularly choosy about which advisors ...

While total segment revenue declined 6.6% year-over-year due to weak truckload (TL) demand and lower rates, gross margins ...

The firm’s CEO cited a “very competitive” recruiting market in 2024, but forecasts a better 2025 as longer-term efforts pay ...

ST. LOUIS (AP) — ST. LOUIS (AP) — Stifel Financial Corp. (SF) on Wednesday reported net income of $244 million in its fourth quarter. The company, based in St. Louis, said it had earnings of $2.09 per ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.